Interestingly, for AML treatment, TKI can increase the mature glycosylated form of FLT3 and reposition the FLT3-ITD and FLT3-D835Y mutants, which are originally located in the endoplasmic reticulum, to the cell membrane. The gene discussed is FLT3; the disease is acute myeloid leukemia.